It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CXXIF’s FA Score shows that 1 FA rating(s) are green whileETST’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CXXIF’s TA Score shows that 3 TA indicator(s) are bullish while ETST’s TA Score has 3 bullish TA indicator(s).
CXXIF (@Pharmaceuticals: Generic) experienced а +8.13% price change this week, while ETST (@Pharmaceuticals: Generic) price change was +5.13% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +4.25%. For the same industry, the average monthly price growth was +10.98%, and the average quarterly price growth was +78.05%.
A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
CXXIF | ETST | CXXIF / ETST | |
Capitalization | 38.1M | 60.2M | 63% |
EBITDA | 4.72M | 2.52M | 188% |
Gain YTD | 57.550 | 64.000 | 90% |
P/E Ratio | N/A | 22.78 | - |
Revenue | 32.1M | 30.5M | 105% |
Total Cash | 2.66M | 1.62M | 164% |
Total Debt | 12.9M | 987K | 1,307% |
CXXIF | ETST | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 26 | 87 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 97 Overvalued | 75 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 53 | |
SMR RATING 1..100 | 93 | 14 | |
PRICE GROWTH RATING 1..100 | 34 | 56 | |
P/E GROWTH RATING 1..100 | 6 | 69 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ETST's Valuation (75) in the null industry is in the same range as CXXIF (97). This means that ETST’s stock grew similarly to CXXIF’s over the last 12 months.
ETST's Profit vs Risk Rating (53) in the null industry is somewhat better than the same rating for CXXIF (100). This means that ETST’s stock grew somewhat faster than CXXIF’s over the last 12 months.
ETST's SMR Rating (14) in the null industry is significantly better than the same rating for CXXIF (93). This means that ETST’s stock grew significantly faster than CXXIF’s over the last 12 months.
CXXIF's Price Growth Rating (34) in the null industry is in the same range as ETST (56). This means that CXXIF’s stock grew similarly to ETST’s over the last 12 months.
CXXIF's P/E Growth Rating (6) in the null industry is somewhat better than the same rating for ETST (69). This means that CXXIF’s stock grew somewhat faster than ETST’s over the last 12 months.
CXXIF | ETST | |
---|---|---|
RSI ODDS (%) | 1 day ago90% | N/A |
Stochastic ODDS (%) | 1 day ago90% | 1 day ago90% |
Momentum ODDS (%) | N/A | 1 day ago90% |
MACD ODDS (%) | 1 day ago90% | 1 day ago82% |
TrendWeek ODDS (%) | 1 day ago83% | 1 day ago90% |
TrendMonth ODDS (%) | 1 day ago83% | 1 day ago90% |
Advances ODDS (%) | 6 days ago81% | 9 days ago84% |
Declines ODDS (%) | 1 day ago87% | 5 days ago90% |
BollingerBands ODDS (%) | 1 day ago87% | N/A |
Aroon ODDS (%) | 1 day ago82% | N/A |
A.I.dvisor indicates that over the last year, CXXIF has been loosely correlated with GTBIF. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if CXXIF jumps, then GTBIF could also see price increases.
Ticker / NAME | Correlation To CXXIF | 1D Price Change % | ||
---|---|---|---|---|
CXXIF | 100% | -20.33% | ||
GTBIF - CXXIF | 54% Loosely correlated | -12.40% | ||
TCNNF - CXXIF | 53% Loosely correlated | -7.35% | ||
VRNOF - CXXIF | 52% Loosely correlated | -19.33% | ||
TSNDF - CXXIF | 52% Loosely correlated | +1.10% | ||
JUSHF - CXXIF | 47% Loosely correlated | -10.65% | ||
More |
A.I.dvisor tells us that ETST and RSCI have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ETST and RSCI's prices will move in lockstep.
Ticker / NAME | Correlation To ETST | 1D Price Change % | ||
---|---|---|---|---|
ETST | 100% | +7.89% | ||
RSCI - ETST | 22% Poorly correlated | N/A | ||
CXXIF - ETST | 22% Poorly correlated | -20.33% | ||
ESALF - ETST | 14% Poorly correlated | +0.32% | ||
HLTRF - ETST | 12% Poorly correlated | +0.27% | ||
HKMPY - ETST | 10% Poorly correlated | N/A | ||
More |